Therapeutic plasma exchange (TPE) has been shown to hasten recovery in Guillain-Barre syndrome
The Guillain-Barre syndrome
and the 1992-1993 and 1993-1994 influenza vaccines.
Antiretroviral therapy for treatment-naive chronic HIV-1 infection with an axonal variant of Guillain-Barre syndrome
positive for anti-ganglioside antibody: a case report.
Risk of cancer in patients with Guillain-Barre syndrome
(GBS): A population-based study.
is a disorder in which the body's immune system attacks itself, causing muscle weakness and other problems.
is rare, affecting one in 100,000 people, and the cause is not known, but it is often preceded by an infectious illness.
Early electrodiagnostic findings in Guillain-Barre syndrome
affects the peripheral nervous system beginning in the feet or hands and moving into the body trunk.
Vaccination is not recommended for babies less than six months old; people with severe chicken egg allergies, as the flu vaccine is made in chicken eggs; those who have had severe reactions to vaccination in the past; and individuals who developed Guillain-Barre syndrome
within six weeks of a previous vaccination--this rare disorder causes muscle weakness and sometimes paralysis.
residents, were diagnosed with Guillain-Barre Syndrome
(GBS), a rare disease that causes muscle weakness, numbness in the arms and legs, and in some cases paralysis, respiratory problems or even death.
An analysis of side effects among nearly 90 million people in China vaccinated during the 2009-2010 flu season found that only 11 were subsequently diagnosed with Guillain-Barre syndrome
, a rate no greater than what normally appears in the population.
(GBS) is a syndrome that affects the immune system and attacks the peripheral nervous system.
She suffers from the autoimmune disorder Guillain-Barre syndrome
Disorders include paraplegia, radial neuropathy, sensory neuropathy, Fabry's disease, neurogastrointestinal encephalomyopathy, Guillain-Barre syndrome
, POEMS syndrome, leprosy, and autoimmune autonomic ganglionopathy.
The excess risk of developing Guillain-Barre syndrome
associated with receipt of the pandemic influenza A(H1N1) vaccine is less than 1 case per 1 million vaccinations--a rate comparable to that seen for some trivalent seasonal influenza vaccines.